BridgeBio Pharma (BBIO)
(Delayed Data from NSDQ)
$47.37 USD
+0.10 (0.21%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $47.39 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, BridgeBio Pharma, Inc. has a market cap of $8.98B, which represents its share price of $47.27 multiplied by its outstanding shares number of 189.88M. As a mid-cap company, BBIO's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
BBIO 47.37 +0.10(0.21%)
Will BBIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BBIO
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy?
BBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation
Are Medical Stocks Lagging Alignment Healthcare (ALHC) This Year?
Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade
Other News for BBIO
Alnylam: Amvuttra Is Just Getting Started
10 Health Care Stocks Whale Activity In Today's Session
Peloton upgraded, Booking downgraded: Wall Street's top analyst calls
BBIO: Cantor Fitzgerald Reiterates Overweight Rating for BridgeBio Pharma | BBIO Stock News
BridgeBio (BBIO) Coverage Assumed by Raymond James with Optimistic Outlook